<p>Work closely with Alnylam's human genetics, multi-omics, platform and clinical teams to identify promising novel targets. Contribute to Alnylam's target identification efforts that are based on human genetics, literature, academic collaborations, genomic approaches, etc. Design and execute proof of concept experiments in animal and in vitro disease models. Design studies, coordinate activities, and lead from the bench. Oversee lead discovery activities for the selection of drug candidates for further development. Develop assays to monitor target engagement/pharmacodynamic responses. Work with multifunctional teams to shepherd a drug candidate through the lead selection and development process to the clinic. Manage relationships with contract research organizations (CROs) and/or academic collaborators, including development of research plans and data analysis. Mentor junior scientists. Collaborate and communicate results with key stakeholders throughout organization. PhD in biology or biomedical sciences-related field. Post doc or 1-2 years of experience preferred. Strong publication record. Individuals with expertise in muscle biology, muscle metabolism or metabolic disease are strongly encouraged to apply. Existing focus on disease biology and prior experience with mammalian disease models is also preferred. Solid organizational skills and ability to multitask are a must. The successful candidate will have strong interpersonal and communication skills, track record of working on teams, interest in learning new biology and passion for lab work. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by "interfering" with mRNA that cause or contribute to disease. Since our founding in 2002, Alnylam has led the RNAi Revolution and continues to turn scientific possibility into reality. Our culture: Our people-first culture is guided by our core values: fiercely innovative, open culture, purposeful urgency, passion for excellence, and commitment to people, and these values influence how we work and the business decisions we make. Thanks to feedback from our employees over the years, we've been fortunate to be named a top employer around the world. Alnylam is extremely proud to have been recognized as the #1 Large Employer by Boston Globe Top Places to Work in 2023 for the third consecutive year, one of Science Magazine's Top Biopharma Employers, one of America's Most Responsible Companies for 2024 by Newsweek, a Fast Company Best Workplace for Innovators, and a Great Place to Work in Canada, France, Italy, Spain, Switzerland, and UK - among others. At Alnylam, we commit to an inclusive recruitment process and equal employment opportunity. We are dedicated to building an environment where employees can feel that they belong, can bring their authentic selves to work, and achieve to their full potential. By empowering employees to embrace their unique differences at work, our business grows stronger with advanced and original thinking, allowing us to bring groundbreaking medicines to patients. Qualified applicants will receive consideration for employment without regard to their race, color, religion, age, sex, sexual orientation, gender identity or expression, national origin, ethnicity, marital status, protected veteran status, disability, or any other characteristics prohibited by law.</p>